VTAMA Drug Patent Profile

« Back to Dashboard

When do Vtama patents expire, and what generic alternatives are available?

Vtama is a drug marketed by Organon Llc and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.

DrugPatentWatch^® Generic Entry Outlook for Vtama

Vtama was eligible for patent challenges on May 23, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for VTAMA

US Patents:	12
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VTAMA

Paragraph IV (Patent) Challenges for VTAMA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VTAMA	Cream	tapinarof	1%	215272	4	2026-05-26

US Patents and Regulatory Information for VTAMA

VTAMA is protected by fourteen US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,647,649.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	11,590,088
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	10,195,160		Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	12,569,453

International Patents for VTAMA

When does loss-of-exclusivity occur for VTAMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

European Patent Office

Israel

Japan

Mexico

New Zealand

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VTAMA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	104699
Australia	2016263161
Australia	2019203627

VTAMA (tapinarof) investment scenario and patent/IP fundamentals (2026)

Last updated: July 12, 2026

VTAMA (tapinarof) revenue exposure is dominated by (1) near-term unit growth driven by plaque psoriasis demand, (2) defensibility from a compact small-molecule topical IP estate, and (3) US generic entry risk shaped by Orange Book coverage and possible 505(b)(2) or ANDA pathways. The investment case hinges on whether the patent and exclusivity landscape supports sustained premium pricing and whether payer behavior and competitive penetration from other topical dermatology agents compress net pricing faster than underlying demand grows.

What is VTAMA (tapinarof) and why does it matter for investment returns?

VTAMA is a topical, non-steroidal small-molecule treatment for plaque psoriasis. Tapinarof is positioned against topical corticosteroids and emerging non-steroidal dermatology agents, with pricing and formulary access the key variables for earnings durability.

Core investment drivers

• Demand durability in plaque psoriasis and expansion to broader inflammatory dermatoses (if supported by labeling and clinical outcomes).
• Net price and formulary placement in dermatology benefit designs (particularly Medicare Part D equivalents for cash-pay dynamics in commercial settings).
• Competitive intensity in topical psoriasis, including penetration of alternatives in the same prescribing workflows.

Key downside variables

• Faster-than-expected competitive substitution that limits prescription growth.
• Generic or 505(b)(2) launches that force price erosion before core patents or exclusivity expire.
• Adverse manufacturing or supply constraints that interrupt fulfillment and trigger revenue volatility.

How strong is the patent estate for VTAMA (tapinarof) in the US?

For investment underwriting, VTAMA’s valuation sensitivity is tied to how much of US market exclusivity is anchored in enforceable, product-specific patents versus early-expiring process or intermediate patents.

Featured-snippet answer (what matters most)

• The investable question is not total patent count, but whether VTAMA’s Orange Book-listed patents cover:
  (1) the marketed drug substance and/or composition,
  (2) the specific topical formulation, and
  (3) the key method-of-use claims (if any) tied to labeled plaque psoriasis indications.

IP estate components to underwrite

• Composition-of-matter (drug substance) protection for tapinarof.
• Formulation protection for the topical vehicle and concentration.
• Method-of-use or use-type claims linked to plaque psoriasis treatment protocols.
• Manufacturing/process claims that may affect design-around options for ANDA filers.

Practical investment read-through

• A smaller, more tightly drafted estate tends to be cleaner to litigate but can also mean less “coverage depth” if one patent falls.
• If coverage relies on formulation-specific claims, generic risk rises when ANDA applicants can credibly design around excipients/vehicle or demonstrate bioequivalence without infringing.

What patents protect tapinarof for plaque psoriasis (VTAMA) in the US Orange Book?

The Orange Book is the gating dataset for ANDA Paragraph IV and 505(b)(2) transition risk. The investment scenario depends on which patents are listed for the approved VTAMA NDA and whether they are “integral” to the claimed formulation.

Underwriting checklist

• Identify Orange Book drug-product entry and associated patent numbers.
• Map each patent to claim coverage categories:
  • active ingredient or drug substance
  • formulation
  • method of use
  • manufacturing/process
• Track expiration dates and whether any listed patents have already expired, are about to expire, or are tied to pediatric exclusivity extensions or other statutory extensions.

When does VTAMA lose exclusivity in the US (patent expiration vs exclusivity windows)?

Exclusivity is a separate clock from patent expiry. For investment modeling, the relevant timeline is:

• US regulatory exclusivity end (if applicable) for the NDA category and any granted exclusivity extensions.
• Earliest expiration among Orange Book-listed patents (composition, formulation, or method-of-use).
• If relevant, the “typical” Paragraph IV litigation window where ANDA filers may challenge before or at the cliff.

Featured-snippet answer

• VTAMA’s exclusivity runway is the shorter of (a) statutory exclusivity end and (b) earliest Orange Book patent expiration date for patents that cover the marketed product and are not replaced by later-expiring continuations.

What generic entry risks exist for VTAMA (tapinarof) under ANDA or 505(b)(2)?

Generic entry for a topical small molecule typically uses one of two playbooks:

1. ANDA with Paragraph IV challenges to Orange Book patents.
2. 505(b)(2) leveraging published literature or bridging studies, if a pathway is available without direct reliance on full clinical data.

What to underwrite for generic risk

• How many Orange Book patents are listed for the specific strength/dosage form.
• Whether those patents are formulation-specific enough to force infringement analyses rather than simple equivalence.
• Likelihood of Paragraph IV filings once the earliest-expiring patent nears expiry.
• Settlement dynamics. If the brand settles with an early filer, future entry can be delayed or restricted through settlement terms, even if not all patents are strong.

Which companies are challenging VTAMA patents (Paragraph IV) and what does that imply?

Investment relevance comes from:

• The identity of challengers (generic platforms with resources for complex topicals).
• Whether challenges target composition, formulation, or method-of-use patents.
• Whether litigation is active, stayed, or settled, which affects expected launch timing and market share capture.

Featured-snippet answer

• The key signal is whether Paragraph IV challenges are concentrated on the earliest-expiring Orange Book patents. Challenges aimed at later-expiring patents can indicate strategic leverage, not imminent entry.

What patent litigation affects VTAMA (tapinarof) in federal court?

For an investable forecast, you need:

• Case caption(s) tied to the NDA/patent list.
• Filing dates and the patents asserted.
• Current status: dismissed, stayed, trial, appeal, or settlement.

Why litigation status changes valuation

• Active litigation near the critical date increases uncertainty but can also reduce near-term generic entry if stay/temporary restraining order patterns apply.
• Settlements often establish “launch dates” and carve-outs. Those contractual dates can dominate the next 12 to 36 months of revenue planning.

How does VTAMA compare with other topical psoriasis treatments on the investment-relevant dimensions?

A competitive comparison determines whether pricing power persists.

Investment comparison axes

• Efficacy perception and tolerability outcomes driving adherence and persistence.
• Dosing schedule simplicity (once-daily topical adherence) relative to competitors.
• Payer uptake and preferred drug status.

Competitive set to model (typical topical psoriasis mix)

• Topical corticosteroids (low price but adherence and safety constraints).
• Vitamin D analogs and calcineurin inhibitors (varies by patient profile and guideline adoption).
• Emerging non-steroidal agents with anti-inflammatory mechanisms.

What formulations are protected by VTAMA (tapinarof) patents?

For topicals, formulation patents can be the highest-leverage IP for keeping pricing premium.

What formulation claims usually cover

• Specific topical concentration ranges.
• Vehicle composition and excipient selection (solvent system, permeation enhancers, stabilizers).
• Manufacturing constraints that affect stability, delivery, or shelf-life.

Design-around impact

• If patents narrowly tie coverage to a specific vehicle, generics may attempt reformulation.
• If patents cover broader concentration ranges or functional excipient categories, design-around becomes harder and litigation risk rises.

Does VTAMA have method-of-use patent protection for plaque psoriasis?

Method-of-use claims can delay entry even if composition claims are weak, but only if the generic would practice the covered method for the labeled indication.

Investment relevance

• Strong method-of-use claims can reduce “non-infringing” marketing strategies.
• If the labeled indication and dosing regimen align closely with method claims, generic carve-outs are harder.

What is the FDA status of VTAMA and how does that impact commercial durability?

FDA status impacts launch timelines for any authorized competitors and shapes how quickly payers can adopt substitutes.

Investment impacts of FDA posture

• Label breadth and any expansions increase the addressable prescribing population.
• Safety communications can reduce prescriber confidence and drive utilization down.
• Any regulatory delays in supply, manufacturing changes, or post-marketing commitments can create short-term revenue volatility.

Is VTAMA at risk from biosimilars or only generics?

VTAMA is a small-molecule topical drug, so biosimilar risk is not the relevant competitive threat. The core competitive threat is generic and 505(b)(2) competition.

Investment implication

• Underwrite price erosion and entry timing via Orange Book and ANDA litigation, not biologics pathways.

How many patents cover VTAMA and what is the expiration schedule concentration risk?

A common failure mode in brand valuation is expiration “clustering,” where multiple patents terminate within a short period.

What to compute for underwriting

• Count of Orange Book patents by type (composition, formulation, method).
• Earliest expiration date cluster window (for example, 0–24 months from valuation).
• Whether any “staggered” patents exist or whether the estate has a single critical cliff.

Revenue exposure: what share of dermatology pricing power could VTAMA lose on generic entry?

Price erosion depends on:

• time-to-entry (how fast generics arrive after the first patent cliff)
• number of entrants (single filer vs multiple filers)
• contract terms with pharmacy benefit managers and wholesalers
• physician switching inertia in dermatology

Investment modeling approach

• Build a base case with market penetration curves for topicals post-generic.
• Add scenarios:
  • delayed entry due to litigation and settlements
  • accelerated entry due to successful design-around or weak coverage
  • partial protection where only some strengths or formulations are covered

Commercial scenario framework: bull, base, bear around IP and competition

Bull case

• Patent and exclusivity timeline delays generic entry.
• Pricing holds longer due to payer inertia and superior tolerability/adherence.

Base case

• Competitive pressure increases but avoids immediate margin collapse.
• Any generic entry occurs on a defined timeline with partial market share retention.

Bear case

• Paragraph IV challenges succeed on key earliest-expiring patents.
• Price compression starts earlier than expected with multiple challengers and fast formulary substitution.

Key Takeaways

• VTAMA’s investment profile is primarily determined by Orange Book patent coverage and the litigation/settlement path for any Paragraph IV challenges, not by biosimilar risk.
• The highest valuation risk is an early, concentrated expiration cliff tied to formulation or core product claims that enable faster ANDA/505(b)(2) entry.
• The main upside comes from sustained premium pricing and payer acceptance if exclusivity and patent enforcement keep generics out long enough for demand momentum to translate into durable revenue.

FAQs

1. What Orange Book patents are listed for VTAMA (tapinarof) and which expire first?
2. Do Paragraph IV challenges for topical drugs like VTAMA typically target formulation patents or composition patents?
3. How do settlements in ANDA patent cases affect the actual generic launch date for VTAMA?
4. Can a 505(b)(2) pathway bypass VTAMA’s formulation patents, and what drives approval timing?
5. What data matter most to investors when assessing VTAMA’s ability to maintain net pricing after generic entry?

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Patent and Trademark Office (USPTO). Patent Examination and Publication data (tapinarof-related publications). USPTO.